Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 19.98 HKD -0.84% Market Closed
Market Cap: 62.4B HKD
Have any thoughts about
Sinopharm Group Co Ltd?
Write Note

Sinopharm Group Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sinopharm Group Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Sinopharm Group Co Ltd
HKEX:1099
Pre-Tax Income
ÂĄ18.2B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
13%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Pre-Tax Income
ÂĄ7.2B
CAGR 3-Years
-5%
CAGR 5-Years
5%
CAGR 10-Years
7%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Pre-Tax Income
ÂĄ2.9B
CAGR 3-Years
-13%
CAGR 5-Years
6%
CAGR 10-Years
15%
C
China National Medicines Corp Ltd
SSE:600511
Pre-Tax Income
ÂĄ2.9B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
17%
Huadong Medicine Co Ltd
SZSE:000963
Pre-Tax Income
ÂĄ3.9B
CAGR 3-Years
12%
CAGR 5-Years
4%
CAGR 10-Years
13%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Pre-Tax Income
ÂĄ2B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
10%
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Market Cap
62.4B HKD
Industry
Health Care

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
78.18 HKD
Undervaluation 74%
Intrinsic Value
Price

See Also

What is Sinopharm Group Co Ltd's Pre-Tax Income?
Pre-Tax Income
18.2B CNY

Based on the financial report for Jun 30, 2024, Sinopharm Group Co Ltd's Pre-Tax Income amounts to 18.2B CNY.

What is Sinopharm Group Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
13%

Over the last year, the Pre-Tax Income growth was -6%. The average annual Pre-Tax Income growth rates for Sinopharm Group Co Ltd have been 2% over the past three years , 6% over the past five years , and 13% over the past ten years .

Back to Top